Lisocabtagene maraleucel Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Lisocabtagene maraleucel Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
30
Registered trials
160
Result records
1
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Lisocabtagene maraleucel can convert its Autologous CAR-T profile and CD19 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Lisocabtagene maraleucel (query alias: Lisocabtagene maraleucel) |
|---|---|
| Modality / target | Autologous CAR-T; CD19; CD19 modulators, T lymphocyte replacements |
| Highest global status | Approved |
| Originator | Fred Hutchinson Cancer Research Center, Bristol Myers Squibb Co. |
| Active developers | Bristol-Myers Squibb Pharma EEIG, Bristol Myers Squibb Co., Bristol-Myers Squibb KK |
The MCP disease footprint includes Mantle cell lymphoma recurrent, Mantle cell lymphoma refractory, Marginal zone lymphoma recurrent. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| ChiCTR2600121485 | Phase 4 | Not yet recruiting | 30 | Progression-free survival |
| NCT07015242 | Phase 2 | Recruiting | 65 | Progression-free Survival (PFS) |
| NCT07194980 | Phase 2 | Recruiting | 20 | Complete response (CR) |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Comparative effectiveness and safety of axicabtagene ciloleucel versus lisocabtagene maraleucel in large B-cell lymphoma: A real-world target trial emulation.
Not Applicable; n=1311; evaluation: Positive. Reported fields: CRS: HR = 0.86(95.0% CI, 0.66 - 1.11); CRS: HR = 0.86(95.0% CI, 0.66 - 1.11)
Real-world outcomes of lisocabtagene maraleucel (liso-cel) in patients (pt) with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL): First results from CIBMTR.
Not Applicable; n=45; evaluation: Positive. Reported fields: AE = Among pts with any-grade (gr) cytokine release syndrome (80%; gr ≥ 3, 4%) or immune effector cell-associated neurotoxicity syndrome (36%; gr ≥ 3, 13%), no gr 5 events occurred. Clinically significant infections were reported in 40% of pts, and at 30 d after infusion, 18% had persistent gr 4 thrombocytopenia and/or neutropenia. Rates were low of HLH/MAS (7%), second primary malignancies (2%; 1 case of basal cell carcinoma 34 d postinfusion), tumor lysis syndrome (7%), and gr 3/4 organ toxicity (9%).
Outcomes of lisocabtagene maraleucel (liso-cel) in patients (pt) with relapsed or refractory (R/R) mantle cell lymphoma (MCL): First real-world data from the CIBMTR.
Not Applicable; n=94; evaluation: Positive. Reported fields: AE(cytokine release syndrome) = 65.0 %
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Lisocabtagene maraleucel addresses Mantle cell lymphoma recurrent, Mantle cell lymphoma refractory, Marginal zone lymphoma recurrent. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Autologous CAR-T—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 1 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2013-10-01 | Juno Therapeutics entered into a license agreement with FHCRC | Not disclosed | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Genetically engineered t cells expressing a CD19 chimeric antigen receptor (CAR) and uses thereof for allogeneic cell therapy”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Class crowding and differentiation versus other PD-(L)1/VEGF agents
- Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
- Biomarker strategy, indication selection, and head-to-head endpoint execution
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
